Effect of tongxinluo capsule on platelet aggregation function in patients with aspirin resistance.
- Author:
Cheng-hua YIN
1
;
Da-peng BI
;
Min DU
Author Information
- Publication Type:Journal Article
- MeSH: Adenosine Diphosphate; metabolism; Adult; Aged; Aged, 80 and over; Aspirin; pharmacology; Collagen; metabolism; Coronary Disease; blood; drug therapy; Drug Resistance; Drugs, Chinese Herbal; pharmacology; Female; Humans; Male; Middle Aged; Platelet Aggregation; drug effects
- From: Chinese Journal of Integrated Traditional and Western Medicine 2010;30(4):380-382
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of Tongxinluo Capsule (TXLC) on platelet aggregation in patients of coronary heart disease (CHD) with aspirin resistance (AR).
METHODSPatients with AR were screened out from 330 CHD patients, who had regularly taken aspirin (100 mg/d) for more than one month, by testing platelet aggregation level after adenosine diphosphate (ADP) and collagen (COL) induction. They were randomly assigned to three groups: the combined treatment group treated by TXLC + aspirin, the TXL group treated by TXLC alone and the AS group treated by aspirin alone, at the dose of TXLC 3 capsules thrice a day, and that of aspirin 100 mg/d. The therapeutic course for all was one month. Patients' platelet aggregation was measured before and after 1-month treatment.
RESULTSEighty-nine patients with AR were screened out from the 330 CHD patients, the occurrence rate being 26.97%. Platelet aggregation was significantly decreased after 1-month treatment in the combined treatment group and the TXL groups (P < 0.05), but changed insignificantly in the AS group, the difference between the former two and the latter group was statistically significant (P < 0.05).
CONCLUSIONTXLC has definite effect in reducing the ADP + COL induced platelet aggregation.
